Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Aduro publishes pair of preclinical data papers
July 2015
SHARING OPTIONS:

BERKELEY, Calif.—Aduro Biotech Inc. has published articles in both Cell Reports and Science and Translational Medicine that describe the antitumor activity of its synthetic cyclic dinucleotide (CDN) molecules and their ability to specifically target the human STING pathway. In the Cell Reports paper, the researchers detailed how injecting tumors with ADU-S100 caused profound regression of established melanoma, colon cancer and breast cancer tumors in mouse models, both in injected and untreated lesions. Treating a single tumor launched a systemically effective T cell response that prevented metastases, with a durable response, long-lived immunologic memory and lasting antitumor protection. The second paper related that the increased antitumor activity of GVAX cancer vaccines developed with Aduro’s CDN molecules was STING-dependent and correlated with increased activation of dendritic cells and antigen-specific CD8+ T cells. Tumors in treated mice demonstrated significant up-regulation of PD-L1, and the combination therapy induced significant regression or elimination of tumors that failed to respond to treatment with anti-PD-1 inhibitors alone.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2017 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.